
Opinion|Videos|February 28, 2025
Looking Ahead: Strategic Planning for Biosimilar Integration
A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are you preparing for the increasing number of biosimilars entering the market?
- What changes to your biosimilar strategy do you anticipate making in the next 1 to 2 years?
- How do you see the role of biosimilars evolving at your institution and on a broader scale?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























